Scholarlink

<p>Few studies analyzed the impact of bone marrow (BM) or peripheral blood stem cells (PBSC) on outcomes after haploidentical transplantation using post-cyclophosphamide (Haplo-PTCY). We analyzed 8854 adults with malignant disorders, given a first Haplo-PTCY. BM cells was used in 2914 and PBSC in 5940 patients. Multivariate models were built adjusting for the statistical differences between the 2 groups. Median follow-up time for survivors in the BM and PBSC groups were 48 and 30 months, respectively. Neutrophil Engraftment was observed in 92.4% of BM and 93.7% of PBSC recipients (<i>p</i> = 0.01). In a multivariate analysis, use of PBSC compared to BM, was associated with higher incidence of acute (HR:1.53; <i>p</i> &lt; 0.0001) and chronic GVHD (HR:1.34; <i>p</i> &lt; 10-3), increased non-relapse mortality (HR:1.22; <i>p</i> = 0.002), similar risk of relapse (HR:1.02; <i>p</i> = 0.79), and decreased overall survival (OS)(HR:1.13; <i>p</i> = 0.008); progression-free survival (PFS)(HR:1.11; <i>p</i> = 0.024) and GVHD-Relapse free survival (GRFS) (HR:1.2; <i>p</i> &lt; 10–3). In conclusion, use of BM cells is associated with better outcomes compared to PBSC after Haplo-PTCY. Future studies should investigate better GVHD prophylaxis in the PBSC-Haplo-PTCY setting and the association of measured T-cell or other subpopulations of lymphocyte content in the PBSC graft.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMT

  • 期刊论文

  • 发表日期：

    2025年11月5日

查看全文
  • Vanderson Rocha,
  • Myriam Labopin,
  • Anna Maria Raiola,
  • Raynier Devillier,
  • Stefania Bramanti,
  • Fabio Ciceri,
  • Jose Luiz Diez-Martin,
  • Yener Koc,
  • Johanna Tischer,
  • Simona Sica,
  • Mohamad Mohty,
  • Zafer Gülbas,
  • Aleksandr Kulagin,
  • Lucía López Corral,
  • Jacques Emmanuel Galimard,
  • Anna Sureda,
  • Annalisa Ruggeri

摘要

Few studies analyzed the impact of bone marrow (BM) or peripheral blood stem cells (PBSC) on outcomes after haploidentical transplantation using post-cyclophosphamide (Haplo-PTCY). We analyzed 8854 adults with malignant disorders, given a first Haplo-PTCY. BM cells was used in 2914 and PBSC in 5940 patients. Multivariate models were built adjusting for the statistical differences between the 2 groups. Median follow-up time for survivors in the BM and PBSC groups were 48 and 30 months, respectively. Neutrophil Engraftment was observed in 92.4% of BM and 93.7% of PBSC recipients (p = 0.01). In a multivariate analysis, use of PBSC compared to BM, was associated with higher incidence of acute (HR:1.53; p < 0.0001) and chronic GVHD (HR:1.34; p < 10-3), increased non-relapse mortality (HR:1.22; p = 0.002), similar risk of relapse (HR:1.02; p = 0.79), and decreased overall survival (OS)(HR:1.13; p = 0.008); progression-free survival (PFS)(HR:1.11; p = 0.024) and GVHD-Relapse free survival (GRFS) (HR:1.2; p < 10–3). In conclusion, use of BM cells is associated with better outcomes compared to PBSC after Haplo-PTCY. Future studies should investigate better GVHD prophylaxis in the PBSC-Haplo-PTCY setting and the association of measured T-cell or other subpopulations of lymphocyte content in the PBSC graft.